Sahajanand Medical IPO Final Day: GMP ₹17
It’s the final bell for the Sahajanand Medical IPO! Today marks Day 5, the closing day for this mainboard offering on the NSE. Investors have had a full five days to consider their options for Sahajanand Medical, and the subscription numbers are now the focus for everyone eagerly watching this IPO. We’ll break down the latest subscription figures and what the Grey Market Premium (GMP) is telling us as the window to invest officially closes.
| Date | GMP | Est. Listing |
|---|---|---|
| 22 Oct | +₹18 | ₹362 |
| 21 Oct | +₹22 | ₹366 |
| 20 Oct | +₹25 | ₹369 |
| 19 Oct | +₹23 | ₹367 |
| 18 Oct | +₹28 | ₹372 |
Subscription Status
As of the closing bell on Day 5, the subscription figures for Sahajanand Medical are zero across all categories: Retail, Non-Institutional Investors (NII), and Qualified Institutional Buyers (QIB). This is quite unusual for a closing day, and it’s something that could concern potential investors. Typically, by Day 5, you’d expect to see significant subscription numbers, especially in the Retail segment which often drives early interest. The lack of any reported subscription across the board might indicate a few things. It could mean a significant number of applications were processed right at the very end, or it could signal a more cautious approach from investors. We’ll need to see the final, official figures once they’re released to get a clearer picture. However, seeing ‘0x’ across the board on the closing day itself is definitely a talking point.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 3.04x | |
| NII / HNI | 14.64x | |
| QIB | 34.70x | |
| Total | 34.70x |
GMP Update
Now, let’s talk about the Grey Market Premium (GMP). The current GMP for Sahajanand Medical stands at ₹17. Interestingly, this GMP has remained unchanged from yesterday’s ₹17. This stable, albeit modest, GMP suggests that the market sentiment hasn’t drastically shifted overnight. At an issue price of ₹344, a GMP of ₹17 translates to an expected listing price of around ₹361 (Issue Price + GMP). While a positive GMP is always encouraging, a figure this close to the issue price often points to a rather flat listing, or at best, a moderate gain. It doesn’t scream ‘blockbuster debut’, but it also doesn’t signal a potential down-listing. It’s a middle-ground indicator, and its stability throughout the latter half of the subscription period is noteworthy.
Should You Apply?
Making a decision on the last day is always about weighing the available data. The IPO period for Sahajanand Medical was from October 15th to October 19th, 2026. With the issue price at ₹344 and an expected listing of ₹361 based on the current GMP of ₹17, the potential upside is around 4.9%. This is a relatively small gain. The subscription numbers, or rather the lack thereof reported at the close of Day 5, adds another layer to this. Investors often look for robust subscription figures as a sign of strong demand, which can translate into a better listing. However, we’re relying on preliminary data here, and the final numbers could surprise us. It’s always wise to remember that GMP is an unofficial indicator and not a guarantee of listing gains. As per SEBI advisories, investors should conduct their own due diligence and consider their risk appetite before investing. The lot size for this IPO is 43 shares, so any investment would involve multiples of this. The bottom line is, if you’re looking for aggressive listing gains, this GMP might not be enough to excite you. However, if you’re a long-term investor with confidence in Sahajanand Medical’s fundamentals, and the issue price presents a reasonable entry point, then the current market indicators might be less of a concern.